Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area
- 31 March 2020
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 30 (8) , 4234-4241
Abstract
Objectives The loss of skeletal muscle mass is widely considered a predictor of poor survival and toxicity in breast cancer patients. The aim of this study is to evaluate if there is pectoralis muscle area (PMA) variation, reflecting loss of skeletal muscle mass, on consecutive MRI examinations after neoadjuvant chemotherapy. Methods The retrospective study protocol was approved by our institutional review board. A total of n = 110 consecutive patients (mean age 56 ± 11 years) who were treated with neoadjuvant chemotherapy (NAC) for histologically proven primary breast cancer between January 2017 and January 2019 and in whom tumor response was checked with standard breast MRI were included. Two radiologists calculated the pectoralis muscle cross-sectional area before and after NAC. Results Time between the MRI examinations, before starting NAC and after completing NAC, was 166.8 ± 50 days. PMA calculated pre-NAC (8.14 cm2) was larger than PMA calculated post-NAC (7.03 cm2) (p < 0.001). According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, there were no significant differences between responders (complete or partial response) and non-responders (p = 0.362). The multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI exams, estrogen and progesterone receptor status, human epidermal growth factor receptor status (HER-2), Ki-67 expression, lymph node status, RECIST criteria, histological type, average lesion size, molecular categories, and grade. Inter-reader (k = 0.72) and intra-reader agreement (0.69 and 0.71) in PMA assessment were good. Conclusions Pectoralis muscle mass varies in breast cancer patients undergoing NAC and this difference can be estimated directly on standard breast MRI. Key Points • Pectoralis muscle area variation reflects loss of skeletal muscle mass. • Pectoralis muscle area on MRI is reduced after NAC. • Pectoralis muscle mass loss seems independent from other variables.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic reviewCancer Treatment and Research Communications, 2019
- Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRIEuropean Radiology, 2018
- Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast CancerJAMA Oncology, 2018
- Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclinesOncotarget, 2018
- Impact of body composition on outcome in patients with early breast cancerSupportive Care in Cancer, 2017
- Muscle strength in breast cancer patients receiving different treatment regimesJournal of Cachexia, Sarcopenia and Muscle, 2016
- Breast MRI: EUSOBI recommendations for women’s informationEuropean Radiology, 2015
- Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL StudyJournal of Cancer Survivorship, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working groupEuropean Journal of Cancer, 2010